浅析我国药品专利制度--以药品专利与健康权的关系为视角  

A Brief Analysis of China’s Pharmaceutical Patent System--From the Perspective of the Relationship between Pharmaceutical Patents and the Right to Health

作　　者：胡梦婷 HU Mengting(School of Civil,Commercial and Economic Law,China University of Political Science and Law,Beijing 100088,China)

机构地区：[1]中国政法大学民商经济法学院,北京100088

出　　处：《湖州师范学院学报》2020年第3期83-90,共8页Journal of Huzhou University

基　　金：国家大学生创新创业训练计划项目“网络知识产权犯罪研究”(201710357115)。

摘　　要：药品具有维系人类生命健康的特殊性,自TRIPS协议将药品纳入专利保护范围以来,药品专利与健康权之间的冲突在发展中国家屡见不鲜;尽管TRIPS协议在演进过程中提供了部分理论指导与具体解决制度,但在协调冲突时仍具有一定的局限性。我国作为最大的发展中国家,也存在着药品研发水平相对落后、健康权难以保障等问题。为此,相关药品立法不断引入国际协调机制,本次《专利法》第四次修改草案更是针对性地提出了创新药保护期延长的例外性规定,本文亦旨在为完善我国药品专利制度提供法律对策。Medicine have the particularity of maintaining human life and health. Since TRIPS included medicine into the scope of patents protection, the conflict between pharmaceutical patents protection and the right to health has been common in poor countries. Although TRIPS has provided some theoretical guidance and specific solutions for the coordination of conflicts in the evolution process, its contents have certain limitations. As the largest developing country, China also has some problems, such as the relatively backward level of medicine research and the difficulty in ensuring the right to health. To this end, relevant medicine legislation constantly introduces international coordination mechanism, the fourth amendment draft of the patent law is also targeted to put forward the exception provisions for the extension of the protection period of innovative medicine, and this paper also aims to provide legal countermeasures for improving China’s drug patent system.

关 键 词：药品专利 健康权 冲突 协调 法律对策 

分 类 号：D923.42[政治法律—民商法学]